Prof. RAMAZAN İDİLMAN

Articles 269

1. De Novo Malignancies after Liver Transplantation: A Multicenter Cohort Study of Incidence, Timing, and Outcomes

DANIŞ N., DÖNGELLİ H., ÜNEK T., Bacakoğlu A., Turan İ., Karasu A. Z., et al.

The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology , vol.37, no.4, pp.510-523, 2026 (SCI-Expanded, Scopus, TRDizin)

2. Liver Failure, Hepatic Encephalopathy, and Infection Contribute to Mortality Risk in a Global Cirrhosis Cohort

Bajaj J. S., Silvey S., Mullan A., Choudhury A., Wong F., George J., et al.

Clinical Gastroenterology and Hepatology , vol.24, no.2, pp.453, 2026 (SCI-Expanded, Scopus)

3. Ten-Year Follow-Up After 96 Weeks Treatment With Peginterferon Plus Tenofovir in Hepatitis D (HIDIT-II): Improved Clinical Outcome After Combination Therapy

Yurdaydin C., Kahlhöfer J., Caruntu F. A., Yalcin K., GÜREL S., Akarca U. S., et al.

United European Gastroenterology Journal , vol.14, no.1, 2026 (SCI-Expanded, Scopus)

4. Risk Factors for Primary Sclerosing Cholangitis Recurrence Following Liver Transplantation: A Multicenter Retrospective Analysis

Adali G., Acar S., Harputluoğlu M., YILMAZ T. U., KARAKAYALI H., Istemihan Z., et al.

Clinical Transplantation , vol.40, no.1, 2026 (SCI-Expanded, Scopus)

5. Chronic kidney disease in cirrhosis: a study of inpatients from a global perspective

Wong F., Adebayo D., George J., İDİLMAN R., Hayes P. C., Alvares-da-Silva M. R., et al.

Gut , 2026 (SCI-Expanded, Scopus)

6. Enhancement of Inpatient Mortality Prognostication With Machine Learning in a Prospective Global Cohort of Patients With Cirrhosis With External Validation

Silvey S., Kamath P. S., George J., Choudhury A., Xie Q., Topazian M., et al.

Gastroenterology , vol.170, no.1, pp.148-160, 2026 (SCI-Expanded, Scopus)

7. Machine Learning Models Using Hospital Admission Characteristics Do Not Optimally Predict Nosocomial Infection Development in a Global Cirrhosis Cohort

Silvey S., Choudhury A. K., Kamath P. S., Xie Q., Wong F., Hayes P. C., et al.

American Journal of Gastroenterology , 2026 (SCI-Expanded, Scopus)

8. Pre-transplant predictors of 3-Month survival following liver transplantation for acute liver failure in adult and pediatric patients in Türkiye

Turan İ., Akarca U. S., Aladağ M., Harputluoğlu M., YILMAZ S., Gençdal G., et al.

Scientific Reports , vol.15, no.1, 2025 (SCI-Expanded, Scopus)

9. Histological disease progression in patients with metabolic dysfunction–associated steatotic liver disease using paired liver biopsy

Turan Gokce D., Ekelik M., Gumussoy M., Kiremitci S., Bodakci E., Yilmaz V., et al.

European Journal of Gastroenterology and Hepatology , 2025 (SCI-Expanded, Scopus)

10. The impact of long-term potent antiviral therapy on the natural course of disease in patients with hepatitis B virusrelated cirrhosis

Kilic G., Guvenir T., BODAKÇİ E., MELEKOĞLU ELLİK Z., GÖKCAN H., İDİLMAN R.

Hepatology Forum , vol.6, no.4, pp.141-145, 2025 (Scopus)

11. Efficacy and tolerability of tenofovir alafenamide fumarate prophylaxis in HBV-infected individuals receiving chemo/ immunosuppressive therapy

DİLBER F., DURAK S., DEMİR M., YILDIRIM A. E., MELEKOĞLU ELLİK Z., ADANIR H., et al.

Hepatology forum , 2025 (ESCI, Scopus, TRDizin)

12. Updates on Recent Advancements in Hepatitis D Virus Treatment

Bardak A. E., Ozturk N. B., Gurakar M., Sequeira L., Yildiz E., Ozmert E. H., et al.

Viruses , vol.17, no.8, 2025 (SCI-Expanded, Scopus)

13. Hepatic steatosis is associated with HBSAG seroclearance in patients with chronic hepatitis B virus infection but it is also associated with disease progression

Bodakçı E., KİREMİTCİ S., MELEKOĞLU ELLİK Z., Koç Ö., GÜMÜŞSOY M., YILMAZ V., et al.

Hepatology forum , 2025 (ESCI, Scopus, TRDizin)

14. Ornidazole-Induced Liver Injury: The Clinical Characterization of a Rare Adverse Reaction and Its Implications from a Multicenter Study

Çalışkan A. R., Turan I., Vatansever S., Weninger J., Şamdancı E. T., AKATLI A. N., et al.

Biomedicines , vol.13, no.7, 2025 (SCI-Expanded, Scopus)

15. Outcomes of Transjugular Intrahepatic Portosystemic Shunt Procedures in a Very-Low-Volume Institution: A Retrospective Single-Center Study

çelebioğlu E. C., ULUDAĞ S., İDİLMAN R., GÖKCAN H., ÜSTÜNER E., MELEKOĞLU ELLİK Z., et al.

Journal of Gastrointestinal and Abdominal Radiology , 2025 (Peer-Reviewed Journal)

16. The efficacy of magnetic resonance elastography in predicting oesophageal varices in patients with chronic liver disease

Adigüzel M., ERDEN G. A., KURU ÖZ D., Bodakcı E., İDİLMAN R.

Polish Journal of Radiology , vol.90, 2025 (ESCI, Scopus)

17. Mushroom Intoxication in Türkiye: A Nationwide Cohort Study Based on Demographic Trends, Seasonal Variations, and the Impact of Climate Change on Incidence

Gökçe D., Ari D., Ata N., GÖKCAN H., İDİLMAN R., Ülgü M. M., et al.

Turkish Journal of Gastroenterology , vol.36, no.1, pp.61-66, 2025 (SCI-Expanded, Scopus, TRDizin)

18. Assessing hepatic steatosis by magnetic resonance in potential living liver donors

Kuru Öz D., Ellik Z., Gürsoy Çoruh A., Adıgüzel M., Gümüşsoy M., Kiremitci S., et al.

Diagnostic and Interventional Radiology , vol.30, no.6, pp.351-356, 2024 (SCI-Expanded, Scopus, TRDizin)

19. Global prevalence and characteristics of infections and clinical outcomes in hospitalised patients with cirrhosis: a prospective cohort study for the CLEARED Consortium

Cao Z., Wong F., Choudhury A. K., Kamath P. S., Topazian M., Torre A., et al.

The Lancet Gastroenterology and Hepatology , vol.9, no.11, pp.997-1009, 2024 (SCI-Expanded, Scopus)

20. HOSPITALIZED PATIENTS WITH CIRRHOSIS, ESPECIALLY THOSE NOT IN HIGH INCOME COUNTRIES CONTINUE TO HAVE WORSE OUTCOMES REGARDLESS OF WHETHER OUTCOMES WERE STUDIED DURING AND AFTER THE COVID PANDEMIC

Bajaj J., Xie Q., Kamath P. S., Topazian M., Hayes P. C., Torre Torre A., et al.

HEPATOLOGY , 2024 (SCI-Expanded, Scopus)

21. ASSESSMENT OF THE RELATIONSHIP BETWEEN MRI-BASED INTRAMUSCULAR FAT INDICATING SARCOPENIA IN VARIOUS MUSCLE GROUPS AMONG PATIENTS WITH CHRONIC LIVER DISEASE

Er R. E., Akkaya Z., Ünal S., Kuru Öz D., Çelebi M. M., Gökcan H., et al.

HEPATOLOGY , 2024 (SCI-Expanded, Scopus)

22. Changing Trends in the Etiology of Cirrhosis in Türkiye: A Multicenter Nationwide Study

Üçbilek E., Yıldırım A. E., Ellik Z., Turan İ., HAKTANIYAN B., Orucu B., et al.

Turkish Journal of Gastroenterology , vol.35, no.10, pp.772-777, 2024 (SCI-Expanded, Scopus, TRDizin)

23. HEPATIC STEATOSIS IS ASSOCIATED WITH HBSAG CLEARANCE IN PATIENTS WITH CHRONIC HEPATITIS B VIRUS INFECTION

BODAKÇİ E., KİREMİTCİ S., DUMAN S., MELEKOĞLU ELLİK Z., Gumussoy M., GÜVENİR S. T., et al.

HEPATOLOGY , 2024 (SCI-Expanded, Scopus)

24. A Brief Communication of Patients of Patients with Homozygous C282Y Mutation-Related Hereditary Hemochromatosis.

GÖKCAN H., Öz d. K., BODAKÇİ E., İDİLMAN R.

Hepatology forum , vol.5, pp.161-164, 2024 (ESCI, Scopus, TRDizin)

25. A brief communication of patients with homozygous C282Y mutation-related hereditary hemochromatosis

GÖKCAN H., Oz D., BODAKÇİ E., TUNÇ E., İDİLMAN R.

HEPATOLOGY FORUM , vol.5, no.3, pp.161-164, 2024 (ESCI, Scopus, TRDizin)

26. Recurrence of primary sclerosing cholangitis after living donor liver transplantation: experience from turkish registry

Adali G., Harputluoglu M., Kayhan M. A., Gokce D. T., AKARSU M., Daniscomma N., et al.

JOURNAL OF HEPATOLOGY , 2024 (SCI-Expanded, Scopus)

27. A combination of non-invasive tests for the detection of significant fibrosis in patients with metabolic dysfunction-associated steatotic liver disease is not superior to magnetic resonance elastography alone

Duman S., Kuru D., Gumussoy M., KİREMİTCİ S., GÖKCAN H., Ulas B., et al.

EUROPEAN RADIOLOGY , vol.34, no.6, pp.3882-3888, 2024 (SCI-Expanded, Scopus)

28. Histological and clinical disease progression in patients with metabolic dysfunction-associated steatotic liver disease using paired liver biopsy

Ekelik M., Gokce D. T., Gumussoy M., KİREMİTCİ S., Bodakci E., Yilmaz V., et al.

JOURNAL OF HEPATOLOGY , 2024 (SCI-Expanded, Scopus)

29. Portal vein thrombosis increases short-term mortality independent of liver disease severity score among hospitalized patients of decompensated cirrhosis-result from CLEARED consortium

Choudhury A. K., Xie Q., Topazian M., Torre A., Hayes P., Desalegn H., et al.

JOURNAL OF HEPATOLOGY , 2024 (SCI-Expanded, Scopus)

30. Patterns and predictors of postacute discharge location other than home in a global cohort of 3, 678 patients hospitalized with cirrhosis

Seto W., Xie Q., Choudhury A. K., Kamath P. S., Topazian M., Hayes P., et al.

JOURNAL OF HEPATOLOGY , 2024 (SCI-Expanded, Scopus)

31. Natural history of clinical outcomes and hepatic decompensation in metabolic dysfunction-associated steatotic liver disease

Noureddin N., Huang D. Q., Bettencourt R., Siddiqi H., Majzoub A. M., Nayfeh T., et al.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS , no.12, pp.1521-1526, 2024 (SCI-Expanded, Scopus)

32. Chronic hepatitis delta with normal ALT and hepatitis D viremia: unravelling its natural history

Gulnar M. O., Kamal H., Palom A., Arici S., Esteban R., TUNÇ E., et al.

JOURNAL OF HEPATOLOGY , 2024 (SCI-Expanded, Scopus)

33. Geographic disparities in access to liver transplant for advanced cirrhosis: Time to ring the alarm!

Bajaj J. S., Choudhury A., Kumaran V., Wong F., Seto W. K., Alvares-Da-Silva M. R., et al.

American Journal of Transplantation , vol.24, no.5, pp.733-742, 2024 (SCI-Expanded, Scopus)

34. DISEASE PROGRESSION IN PATIENTS WITH METABOLIC DYSFUNCTIONASSOCIATED STEATOTIC LIVER DISEASE USING PAIRED LIVER BIOPSY

Turan D., Ekelik M. M., Gumussoy M., Kiremitci S., Bodakci E., Yilmaz V., et al.

GASTROENTEROLOGY , vol.166, no.5, pp.1642, 2024 (SCI-Expanded, Scopus)

35. A global action agenda for turning the tide on fatty liver disease

Lazarus J. V., Mark H. E., Allen A. M., Arab J. P., Carrieri P., Noureddin M., et al.

Hepatology , vol.79, no.2, pp.502-523, 2024 (SCI-Expanded, Scopus)

36. Five-year follow-up of 96 weeks peginterferon plus tenofovir disoproxil fumarate in hepatitis D

Anastasiou O. E., Caruntu F. A., Curescu M. G., Yalcin K., Akarca U. S., GÜREL S., et al.

Liver International , vol.44, no.1, pp.139-147, 2024 (SCI-Expanded, Scopus)

37. Low liver fat in non-alcoholic steatohepatitis-related significant fibrosis and cirrhosis is associated with hepatocellular carcinoma, decompensation and mortality.

Lee S. W., Huang D. Q., Bettencourt R., Ajmera V., Tincopa M., Noureddin N., et al.

Alimentary pharmacology & therapeutics , vol.59, no.1, pp.80-88, 2024 (SCI-Expanded, Scopus)

38. Changing trends in the etiology of liver transplantation in Turkiye: A multicenter study

Akarsu M., DOLU S., Harputluoglu M., YILMAZ S., Akyildiz M., Gencdal G., et al.

HEPATOLOGY FORUM , vol.5, no.1, pp.3-6, 2024 (ESCI, Scopus)

39. Magnetic resonance elastography-based prediction model for hepatic decompensation in NAFLD: A multicenter cohort study.

Kim B. K., Bergstrom J., Loomba R., Tamaki N., Izumi N., Nakajima A., et al.

Hepatology (Baltimore, Md.) , vol.78, no.6, pp.1858-1866, 2023 (SCI-Expanded, Scopus)

40. Demonstration of therapy response to radioembolization with ⁹⁰Y resin microspheres on ⁶⁸Ga-PSMA PET/MRI in a patient with hepatocellular carcinoma

Özkan E., Demir B., Kuru Öz D., Soydal Ç., Dursun E., Çelebioğlu E. C., et al.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING , vol.51, no.1, pp.316-317, 2023 (SCI-Expanded, Scopus)

41. Adjusted estimate of the prevalence of hepatitis delta virus in 25 countries and territories.

Razavi-Shearer D., Child H., Razavi-Shearer K., Voeller A., Razavi H., Buti M., et al.

Journal of hepatology , 2023 (SCI-Expanded, Scopus)

42. MEFIB-Index and MAST-Score in the assessment of hepatic decompensation in metabolic dysfunction-associated steatosis liver disease-Individual participant data meta-analyses.

Noureddin N., Ajmera V., Bergstrom J., Bettencourt R., Huang D. Q., Siddiqi H., et al.

Alimentary pharmacology & therapeutics , vol.58, no.9, pp.856-865, 2023 (SCI-Expanded, Scopus)

43. A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease

Romero-Gómez M., Lawitz E., Shankar R. R., Chaudhri E., Liu J., Lam R. L., et al.

Journal of Hepatology , vol.79, no.4, pp.888-897, 2023 (SCI-Expanded, Scopus)

44. Type 2 diabetes, hepatic decompensation, and hepatocellular carcinoma in patients with non-alcoholic fatty liver disease: an individual participant-level data meta-analysis.

Huang D. Q., Noureddin N., Ajmera V., Amangurbanova M., Bettencourt R., Truong E., et al.

The lancet. Gastroenterology & hepatology , vol.8, no.9, pp.829-836, 2023 (SCI-Expanded, Scopus)

45. Quality-of-life scores improve after 96 weeks of PEG-IFNa-2a treatment of hepatitis D: An analysis of the HIDIT-II trial

Dinkelborg K., Kahlhöfer J., Dörge P., Yurdaydin C., Hardtke S., Caruntu F. A., et al.

Liver International , vol.43, no.8, pp.1663-1676, 2023 (SCI-Expanded, Scopus)

46. Global disparities in mortality and liver transplantation in hospitalised patients with cirrhosis: a prospective cohort study for the CLEARED Consortium

Bajaj J. S., Choudhury A. K., Xie Q., Kamath P. S., Topazian M., Hayes P. C., et al.

The Lancet Gastroenterology and Hepatology , vol.8, no.7, pp.611-622, 2023 (SCI-Expanded, Scopus)